Эндоксан Drug photo

The description is actual on 22.11.2015

  • Latin name: Endoxan
  • ATH code: L01AA01
  • Active ingredient: Cyclophosphamide (Cyclophosphamide)
  • Producer: Baxter Oncology (Germany), Almirall Prodesfarma (Spain)


In 1 tablet of cyclophosphamide of 50 mg.

Calcium carbonate, macrogoal, polysorbate of a karmelloz of sodium, polividon, sucrose, talc, titanium dioxide, gelatin, calcium hydrophosphate, glitserol, starch, magnesium stearate, silicon dioxide, lactose as excipients.

Release form

Tablets in a sugar cover of 50 mg in packaging on 50 pieces.

Powder in a bottle for preparation of solution for intravenous administrations.

Pharmacological action


Pharmacodynamics and pharmacokinetics


Cyclophosphamide belongs to the alkylating cytostatic drugs. In tumor cells it biotransformirutsya to active metabolites which break synthesis of DNA and RNA, forming cross connections between their threads, block mitotic division and inhibit protein synthesis.


Cyclophosphamide is completely soaked up from a gastrointestinal tract. It is metabolized in a liver with formation of the active alkylating metabolites. The part of them is transformed to inactive metabolites, the part turns into metabolites with cytotoxic action. At intravenous administration at most of concentration of metabolites is defined in 2-3 hours. 5 — 25% of a dose with urine in not changed look are removed by kidneys in the form of metabolites, and. An elimination half-life — 7 hours (adults) and 4 hours (children).

Indications to use

In combination with other antineoplastic drugs it is appointed for a cancer therapy of a neck of uterus, a bladder, a lung, sarcoma of soft tissues, a prostate, a reticulosarcoma.

As immunosuppressive drug is used at the progressing collagenoses, rhematoid and psoriasis arthritis, a nephrotic syndrome, for prevention of graft rejection.


  • cystitis;
  • oppression of function of marrow;
  • the expressed cachexia;
  • urination delay;
  • pregnancy;
  • acute infections;
  • end-stages of diseases;
  • hypersensitivity to drug.

With care it is appointed at a serious illness of a liver, kidneys and hearts, gout, an adrenalectomy, oppression of marrow, a nefrourolitiaza.

Side effects

  • leukopenia, thrombocytopenia, neutropenia;
  • nausea, vomiting, lack of appetite, abdominal pain, stomatitis, diarrhea or lock, colitis, jaundice;
  • alopecia;
  • rash, skin itch, small tortoiseshell;
  • xanthopathy;
  • hemorrhagic urethritis and cystitis, hyperuricemia, renal failure, nephropathy;
  • hemorrhagic myocarditis (seldom);
  • pulmonary fibrosis (at prolonged treatment by high doses);
  • amenorrhea, disturbance of an oogenesis and spermatogenesis sometimes irreversible character;

Endoksan, application instruction (Way and dosage)

The mode of dosing is chosen individually depending on a clinical case. Tablets Endoksan apply inside in 30 min. prior to food, it is possible in 2 h after meal. Usually Endoksan of 50 mg is appointed from 1 to 4 tablets a day (50-200 mg) 2-3 weeks.

At intravenous administration drug is dissolved. Appoint 50-100 mg/sq.m daily. If injections are carried out 3 times a week, then the dose makes 100-200 mg/sq.m, time in 2 weeks — 600-750 mg/sq.m. When performing injections of times month is entered 1500-2000¼ú/sq.m, at the same time the total dose of course treatment has to make 6-14 g.

For the purpose of control of degree of a miyelosupressiya (the maintenance of leukocytes and thrombocytes) regularly do blood test. It is necessary to monitor the analysis of urine on presence of erythrocytes that demonstrates development of hemorrhagic cystitis. At its emergence treatment is stopped. Also interrupt treatment in case of accession of infections as consequences of a heavy miyelosupresiya. It is necessary to abstain from alcohol intake.


In case of overdose strengthening of side reactions, in particular miyelosupressiya or cardiotoxicities takes place. There is no antidote. The symptomatic treatment is carried out.


Use with uricosuric antigouty drugs increases risk of a nephropathy as cyclophosphamide causes the increased formation of uric acid.

At use with Allopyrinolum toxic impact on marrow amplifies.

Inductors of a microsomal oxidation strengthen a cyclophosphamide metabolism that attracts the increased formation of metabolites and strengthening of activity of drug.

Cyclophosphamide increases anticoagulating activity of drugs, strengthens cardiotoxic action of antineoplastic antibiotics of doxorubicine and a daunorubitsin.

Use with immunodepressants (GKS, Azathioprinum, cyclosporine, hlorambutsit, Mercaptopurinum) increases risk of developing of infections and development of secondary tumors.

Use of radiation therapy and the HP causing a miyelosupressiya strengthens oppression of marrow.

Use of cyclophosphamide and lovastatin for patients with the transplanted heart is accompanied by high risk of a necrosis of skeletal muscles and OPN.

Terms of sale

According to the recipe.

Storage conditions

Temperature of storage is 25 °C.

Period of validity

3 years.


Coincidence on the ATH code of the 4th level:

Ledoksina, Endoksan-Asta, Cyclophosphanum, Cyclophosphamide, Cytoxanum.

About Endoksana

All About this drug are connected with existence of side reactions. Practically all patients note a rush of blood to the person at intravenous injections. Also the headache and perspiration disturbed. Cytostatic therapy is accompanied by load of a liver therefore gepatoprotektor were appointed sick and in dynamics the functional condition of a liver during treatment was controlled. Frequent side effects are also oppression of a hemopoiesis (pancytopenia) and a partial or full alopecia (baldness). Growth of hair happens after completion of treatment.


  • Endoksan powder for solution 500 of mg No. 1 flakonbaxter
  • Endoksan powder for solution 200 of mg No. 1 flakonbaxter
  • Endoksan powder for solution 1 of No. 1 flakonbaxter
  • Endoksan of 50 mg No. 50 tabletkibaxter

Drugstore of IFC

  • Endoksan tbl p / about 50 mg No. 50, Baxter Oncology Gmbhgermaniya
to show still


  • Endoksanbaxter Oncology (Germany)


  • Endoksan of other 50 mg No. 50 Asta Medika
Section: Antineoplastic
in more detail

Education: Graduated from Sverdlovsk medical school (1968 - 1971) as "Paramedic". Graduated from the Donetsk medical institute (1975 - 1981) as "An epidemiologist, a hygienist". Passed postgraduate study in the Central scientific research institute of epidemiology Moscow (1986 - 1989). An academic degree – the candidate of medical sciences (degree is awarded in 1989, protection – the Central scientific research institute of epidemiology Moscow). Numerous advanced training courses are studied in epidemiology and infectious diseases.

Experience: Work as the manager of department of disinfection and sterilization of 1981 - 1992. Work as the manager of department of especially dangerous infections of 1992 - 2010. Teaching activity at Medical institute 2010 - 2013.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Endoksan surely consult with the attending physician.